DIA

Report Questions Safety, Ethics of Clinical Trials in India

Tuesday, September 2, 2008 09:00 AM

India’s booming clinical trials business is under scrutiny, following a story in a UK newspaper that set off a flurry of media and regulatory attention.

More... »

MCRC Buyback Spurs 250% Revenue Growth

Tuesday, August 12, 2008 11:00 AM

Multispecialty clinical research site Metroplex Clinical Research Center (MCRC) reported last week that gross revenues have increased 250% since company executives re-assumed control in March 2007.

More... »

Is India Ready For Phase I Studies?

Tuesday, August 15, 2006 08:32 AM

India has come a long way as a center for clinical drug trials, but is the country ready for Phase I studies? I think the short answer - and others would agree - is “no”. Take, for instance, recent comments by Ashwini Kumar, the Drug Controller General of India (DCGI), who spoke recently at the Drug Information Association’s (DIA) Annual Meeting in Philadelphia. Kumar, head of the Central Drug Standard Control Organization (CDSCO), India’s regulatory agency, said that India needed to create an environment for the best quality assurance before embarking on phase I studies...

More... »

Top Stories for the Week of August 7th, 2006

Monday, August 7, 2006 09:05 AM

Top News

More... »

CenterWatch’s 42nd Annual DIA Round Up

Monday, June 26, 2006 10:57 AM

This year’s Drug Information Association (DIA) 42nd annual industry conference, held in Philadelphia, Penn attracted nearly 10,000 attendees from across every sector in the drug development industry. Presenting at the show were over 400 U.S. and close to 200 international companies, from both developed markets and emerging regions around the globe. Nearly 1,000 delegates from 50 countries were scheduled to attend.

More... »

Covance Boosts Phase I/IIa Capacity

Sunday, April 30, 2006 11:18 AM

The search for top quality phase I sites just got even harder as Covance, a leader in the hot early clinical development arena, entered into a definitive agreement to acquire eight early phase clinical development sites from Radiant Research, a site management organization that owns 30 sites, for $65 million. Covance is paying about 2.5 times revenue for the eight sites, which generate $25 million in annual revenue. Seattle-based Radiant Research will continue to operate its phase II through IV sites,but employees associated with the eight phase I sites will become Covance employees. Covance, one of the top global contract research organizations (CROs), has more than 7,300 employees worldwide.

More... »